Capex

(redirected from Fluocinolone)
Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
Related to Fluocinolone: Fluocinolone acetonide

Capex

Capital Expenditure

Payments made in cash or cash equivalents over a period of more than one year. Capital expenditures are used to acquire assets or improve the useful life of existing assets. An example of a capital expenditure is the funding to construct a factory. In accounting, capital expenditures must be capitalized; that is, the expenditure is recognized on a balance sheet gradually over the course of an asset's useful life. Capital expenditures are recorded as liabilities on a balance sheet. They are also called capital outlays. See also: Capital asset.
Mentioned in ?
References in periodicals archive ?
01% fluocinolone acetonide with 2% kojic acid + octinoxate + allantoin in treatment of melasma.
RNIB eye health campaigns manager, Clara Eaglen, said: "We are pleased that NICE has published its Appraisal Consultation Document recommending the use of fluocinolone acetonide for the treatment of chronic diabetic macular oedema (DMO) in certain cases.
Its advanced product candidate, Iluvien(R), is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease.
Amneal's Fluocinolone Acetonide scalp oil, body oil and ear drops are now shipping and available through wholesalers-distributors as well as directly to the trade.
Human health company ACETO Corporation (NasdaqGS:ACET) stated on Friday that it plans to introduce Fluocinolone Acetonide OTIC Oil, 0.
Kompella, of the University of Nebraska Medical Center in Omaha, reported that they found that Fluocinolone inhibited VEGF expression in ARPE-19 cells via its glucorcorticoid receptor activity.
Medidur, a tiny, injectable insert, is being studied as a way to deliver fluocinolone acetonide, a corticosteroid, to the retina for up to three years as a treatment for diabetic macular edema (DME).
Alimera is currently conducting a phase III clinical trial of fluocinolone acetonide in the Medidur[TM] drug delivery system for the treatment of diabetic macular edema.
ATLANTA -- Alimera Sciences, a privately held ophthalmic pharmaceutical company, and pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced that enrollment has begun for the first human (a)pharmacokinetic (PK) study of fluocinolone acetonide (FA) in Medidur[TM], the companies' investigational product for the treatment of diabetic macular edema (DME).
The company added that the micro-insert is a tiny tube about the size of an eyelash that releases the steroid fluocinolone acetonide on a sustained basis for up to 36 months
ILUVIEN (190 micrograms fluocinolone acetonide intravitreal implant in applicator) is a sustained release intravitreal implant used to treat vision impairment associated with chronic DME considered insufficiently responsive to available therapies, providing a therapeutic effect of up to 36 months.
ILUVIEN (190 micrograms fluocinolone acetonide intravitreal implant in applicator) is reportedly Alimera Sciences Inc's sustained release intravitreal implant used to treat vision impairment associated with chronic DME considered insufficiently responsive to available therapies.